PDS Biotechnology Corp — Form 8-K
Filed September 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
PDS Biotechnology announced publication of VERSATILE-002 Phase 2 trial results in JAMA Oncology (September 17, 2026) showing PDS0101 + pembrolizumab achieved 39.3 months median overall survival in ICI-naive HPV16+ head and neck cancer patients (n=53), versus 17.9 months with standard pembrolizumab alone; 36% ORR vs. 19% for standard care; 13.8% Grade ≥3 treatment-related adverse events. Company recently closed $22.3M PIPE financing led by Nant Capital and granted NantWorks one-year exclusive negotiation rights for PDS0101 license.
Why this rating
Peer-reviewed publication of positive Phase 2 data supports PDS0101 clinical profile and justifies partnership strategy; $22.3M financing is ~37% of market cap, providing near-term runway. However, still Phase 2 (non-randomized), PDS0301 remains lead program, and PDS0101 future depends on partner-funded Phase 3.
See more from September 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.